Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.

Autor:	Landovitz RJ; Division of Infectious Diseases, Department of Medicine, Center for AIDS Research and Education & Center for HIV Prevention, David Geffen School of Medicine at University of California, Los Angeles., Zangeneh SZ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Chau G; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington., Grinsztejn B; Laboratório de HIV, Instituto Nacional de Infectologia Evandro Chagas (INI), Fundação Oswaldo Cruz (FIOCRUZ), Rio de Janeiro, Brazil., Eron JJ; Division of Infectious Diseases, University of North Carolina, Chapel Hill., Dawood H; Department of Medicine, University of KwaZulu-Natal, Pietermaritzburg, Durban, South Africa., Magnus M; Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, DC., Liu AY; Bridge HIV, Population Health Division, San Francisco Department of Public Health, California., Panchia R; Perinatal HIV Research Unit, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Soweto, South Africa., Hosseinipour MC; Division of Infectious Diseases, University of North Carolina at Chapel Hill School of Medicine., Kofron R; Division of Infectious Diseases, Department of Medicine, Center for AIDS Research and Education & Center for HIV Prevention, David Geffen School of Medicine at University of California, Los Angeles., Margolis DA; ViiV Healthcare, Research Triangle Park, Durham, North Carolina., Rinehart A; ViiV Healthcare, Research Triangle Park, Durham, North Carolina., Adeyeye A; Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland., Burns D; Division of AIDS, National Institute of Allergy and Infectious Disease, National Institutes of Health, Rockville, Maryland., McCauley M; Science Facilitation Department, FHI 360, Washington DC., Cohen MS; Division of Infectious Diseases, University of North Carolina, Chapel Hill., Currier JS; Division of Infectious Diseases, Department of Medicine, Center for AIDS Research and Education & Center for HIV Prevention, David Geffen School of Medicine at University of California, Los Angeles.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2020 Jan 02; Vol. 70 (2), pp. 319-322.
DOI:	10.1093/cid/ciz439
Abstrakt:	Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic parameters in HIV-uninfected individuals randomized to cabotegravir or a placebo. No differences between arms were found for change in weight or fasting metabolic parameters overall or for subgroups. (© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu